newsfilter
← Latest News
GlobeNewswire·

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian